

LEAD Grants

Qualifying Criteria

In order to qualify, a local organization must be:

- a recognized patient advocacy organization representing individuals who use plasma/recombinant therapies to treat bleeding disorders, immune disorders, Alpha 1 deficiency, Hereditary Angioedema, CIDP or other conditions
- a non-profit organization with a 501(c)(3) tax status
- an organization currently addressing a specific advocacy issue or intending to address such an issue

In order to be considered for a LEAD Grant award, your application must be received by the deadline. Grant recipients will be announced in December

Please answer the following questions and provide as much detail as possible describing the opportunity for LEAD Grant funding. Please feel free to submit any supporting documentation that would be helpful to explain the proposal:

1. What advocacy issue would the LEAD Grant address?
2. What is the desired impact resulting from addressing this issue?
3. Please describe the timeframe for implementing the project, including key milestones.
4. What is your overall projected budget for this advocacy initiative?

All grantees will be required to submit a progress report six months from receipt of funding on activities and achievements to-date.

Any additional relevant information or support material may be included with the application. If this application is being submitted on behalf of a coalition or council, please include letters of support from coalition or council members.

If you would like to learn more, please contact advocacy@cslbehring.com.

Submit completed applications electronically by the deadline of **October 31** to: advocacy@cslbehring.com.

or mail:

CSL Behring

Attn: LEAD Grant Committee

1020 First Avenue

King of Prussia, PA 19406

Phone: 610-878-4000

In order to be considered for a LEAD Grant award, your application must be received by the deadline noted above. Grant recipients will be announced in December

Examples

Examples of advocacy issues for a LEAD Grant:

- Creative advocacy endeavors designed to address a local public policy issue or to positively impact users of plasma-derived and recombinant therapies
- The pursuit of standard-of-care or quality-of-care legislation or regulations for plasma-derived therapies and their recombinant alternatives
- Efforts to defeat or overturn restrictive formulary proposals by a state Medicaid or an insurer
- The pursuit of legislation or regulations that will increase access for individuals to obtain their plasma-derived or recombinant therapy
- The creation of a grassroots program/database to lobby the state legislature